Perspectives on RNA therapeutics, translational development and biotechnology R&D, drawing on experience across discovery, preclinical development, clinical translation, CMC and programme strategy.
AI-enabled mRNA development: What are we actually predicting?
AI-assisted mRNA sequence design and lipid discovery are producing promising results, but what do the models actually predict, and how well do those predictions translate into development decisions? This article examines published examples, their experimental validation and the limits of extrapolating from research models.
From mRNA Experiment to Development Knowledge
Artificial intelligence can support mRNA sequence, formulation and experiment selection, but its usefulness depends on whether each result retains sufficient product and biological context to be interpreted later. This article sets out the provenance, metadata and experimental-design practices that make development data reusable.
Is mRNA Manufacturing Overbuilt?
Published in Advancing RNA and Outsourced Pharma, September 2026
The rapid expansion of mRNA manufacturing capacity after COVID-19 has left the industry with a very different supply landscape. This article looks at the growth in IVT mRNA CDMOs relative to the development pipeline, recent closures and acquisitions, and why headline manufacturing capacity does not necessarily reflect the capacity developers actually need.
The article also considers how demand is shifting towards smaller batches, greater flexibility and faster turnaround as more mRNA programmes move into clinical development.
Read the full article on Advancing RNA
Choosing the first human dose for an mRNA therapeutic
Selecting a first-in-human dose for an mRNA therapeutic requires more than scaling an animal dose. Delivery, translation, encoded-protein pharmacology, safety and biomarkers all contribute to defining a safe and informative starting point.
PK/PD for mRNA therapeutics: what should count as exposure?
For mRNA therapeutics, the easiest exposure to measure may not be the one that drives pharmacology. This article examines how distribution, productive intracellular delivery, encoded-protein exposure and downstream response should be connected.
Common pitfalls in mRNA therapeutic development: from promising science to a viable clinical programme
Promising mRNA science can still become a weak development programme when biology, delivery, CMC, preclinical evidence and clinical translation are treated as separate workstreams. This article looks at the decisions and evidence needed to connect a therapeutic hypothesis to a viable medicine.